Compare EZPW & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZPW | XNCR |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1996 | 2013 |
| Metric | EZPW | XNCR |
|---|---|---|
| Price | $28.37 | $39.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $41.00 | ★ $42.50 |
| AVG Volume (30 Days) | 747.5K | ★ 1.6M |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.09 | ★ 65.36 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $747,954,000.00 | $125,576,000.00 |
| Revenue This Year | $8.21 | $57.39 |
| Revenue Next Year | $7.16 | N/A |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | 2.39 | ★ 13.65 |
| 52 Week Low | $16.50 | $10.38 |
| 52 Week High | $37.13 | $40.60 |
| Indicator | EZPW | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 82.27 |
| Support Level | $27.73 | $11.05 |
| Resistance Level | $31.62 | N/A |
| Average True Range (ATR) | 1.18 | 2.23 |
| MACD | -0.07 | 1.16 |
| Stochastic Oscillator | 24.53 | 97.00 |
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.